Starpharma announced that it has signed a new research partnership with Tianjin Chase Sun Pharmaceutical Co. Ltd. to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.

Under this new DEP® partnership, Starpharma will initially develop DEP® nanoparticle formulations for an anti-infective product for Chase Sun with the view of enhancing its performance and expanding its therapeutic utility. Chase Sun will fund all activities under this agreement and all costs associated with the further development of any DEP® product. In the event that Chase Sun wishes to commercialise any of the resultant DEP® products, a DEP® licence agreement will be entered into with Starpharma.